
Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period
- Michael Lobritz
- February 8, 2022
- kedalionlabs.com
- C Lazor-Blanchet, P Zygoura, U Dafni, …, G Pantaleo, T Calandra, S Meylan
- J Infect, 10.1016/j.jinf.2022.02.001
SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study
- Michael Lobritz
- July 6, 2021
- kedalionlabs.com
- Sylvain Meylan, Urania Dafni, Frederic Lamoth, …, Thierry Calandra, Giuseppe Pantaleo, Catherine Lazor-Blanchet
- BMJ Open, 10.1136/bmjopen-2021-049232
Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1
- Michael Lobritz
- November 12, 2020
- kedalionlabs.com
- Katja Klein, Immaculate Nankya, Gabrielle Nickel, …, Thomas J Hope, Robin J Shattock, Eric J Arts
- J Virol, 10.1128/jvi.01737-20
Understanding and Sensitizing Density-Dependent Persistence to Quinolone Antibiotics
- Michael Lobritz
- Prerna Bhargava
- December 12, 2017
- kedalionlabs.com
- Arnaud Gutierrez, Saloni Jain, Prerna Bhargava, Meagan Hamblin, Michael A Lobritz, James J Collins
- Mol Cell, 10.1016/j.molcel.2017.11.012
Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control
- Michael Lobritz
- January 24, 2017
- kedalionlabs.com
- Sylvain Meylan, Caroline B M Porter, Jason H Yang, …, Sun H Kim, Samuel M Moskowitz, James J Collins
- Cell Chem Biol, 10.1016/j.chembiol.2016.12.015
Bactericidal Antibiotics Induce Toxic Metabolic Perturbations that Lead to Cellular Damage
- Michael Lobritz
- November 14, 2015
- kedalionlabs.com
- Peter Belenky, Jonathan D Ye, Caroline B M Porter, …, Eric G Schwarz, Graham C Walker, James J Collins
- Cell Rep, 10.1016/j.celrep.2015.09.059
Antibiotic efficacy is linked to bacterial cellular respiration
- Michael Lobritz
- June 24, 2015
- kedalionlabs.com
- Michael A Lobritz, Peter Belenky, Caroline B M Porter, …, Daniel J Dwyer, Ahmad S Khalil, James J Collins
- Proc Natl Acad Sci U S A, 10.1073/pnas.1509743112
Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies
- Michael Lobritz
- Prerna Bhargava
- June 6, 2015
- kedalionlabs.com
- Russell J Krom, Prerna Bhargava, Michael A Lobritz, James J Collins
- Nano Lett, 10.1021/acs.nanolett.5b01943
Antibiotics induce redox-related physiological alterations as part of their lethality
- Kyle R Allison
- Michael Lobritz
- May 8, 2014
- kedalionlabs.com
- Daniel J Dwyer, Peter A Belenky, Jason H Yang, …, Alice Y Ting, Graham C Walker, James J Collins
- Proc Natl Acad Sci U S A, 10.1073/pnas.1401876111
Microbial persistence and the road to drug resistance
- Michael Lobritz
- June 18, 2013
- kedalionlabs.com
- Nadia R Cohen, Michael A Lobritz, James J Collins
- Cell Host Microbe, 10.1016/j.chom.2013.05.009
Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc
- Michael Lobritz
- March 27, 2013
- kedalionlabs.com
- Michael A Lobritz, Annette N Ratcliff, Andre J Marozsan, Dawn M Dudley, John C Tilton, Eric J Arts
- Antimicrob Agents Chemother, 10.1128/aac.02511-12
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs
- Michael Lobritz
- February 1, 2012
- kedalionlabs.com
- Kara G Lassen, Andrew M Hebbeler, Darshana Bhattacharyya, Michael A Lobritz, Warner C Greene
- PLoS One, 10.1371/journal.pone.0030176
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA
- Michael Lobritz
- June 1, 2011
- kedalionlabs.com
- Matthew S Lalonde, Michael A Lobritz, Annette Ratcliff, …, Jonathan Karn, Gabriele Varani, Eric J Arts
- PLoS Pathog, 10.1371/journal.ppat.1002038
HIV-1 replicative fitness in elite controllers
- Michael Lobritz
- March 25, 2011
- kedalionlabs.com
- Michael A Lobritz, Kara G Lassen, Eric J Arts
- Curr Opin HIV AIDS, 10.1097/coh.0b013e3283454cf5